prikaz prve stranice dokumenta Current trends in the pharmacotherapy for obesity
  Preuzmi
PDF 247.12 KB
Znanstveni rad - Pregledni rad
Current trends in the pharmacotherapy for obesity
Endocrine Oncology and Metabolism, 2 (2016), 1; 50-59. https://doi.org/10.21040/eom/2016.2.6
Klobučar Majanović, Sanja; Crnčević Orlić, Željka; Štimac, Davor

Citirajte ovaj rad

Klobučar Majanović, S., Crnčević Orlić, Ž. i Štimac, D. (2016). Current trends in the pharmacotherapy for obesity. Endocrine Oncology and Metabolism, 2. (1), 50-59. doi: 10.21040/eom/2016.2.6

Klobučar Majanović, Sanja, et al. "Current trends in the pharmacotherapy for obesity." Endocrine Oncology and Metabolism, vol. 2, br. 1, 2016, str. 50-59. https://doi.org/10.21040/eom/2016.2.6

Klobučar Majanović, Sanja, Željka Crnčević Orlić i Davor Štimac. "Current trends in the pharmacotherapy for obesity." Endocrine Oncology and Metabolism 2, br. 1 (2016): 50-59. https://doi.org/10.21040/eom/2016.2.6

Klobučar Majanović, S., Crnčević Orlić, Ž. i Štimac, D. (2016) 'Current trends in the pharmacotherapy for obesity', Endocrine Oncology and Metabolism, 2(1), str. 50-59. doi: 10.21040/eom/2016.2.6

Klobučar Majanović S, Crnčević Orlić Ž, Štimac D. Current trends in the pharmacotherapy for obesity. Endocrine Oncology and Metabolism [Internet]. 2016. [pristupljeno 17.04.2024.];2(1):50-59. doi: 10.21040/eom/2016.2.6

S. Klobučar Majanović, Ž. Crnčević Orlić i D. Štimac, "Current trends in the pharmacotherapy for obesity", Endocrine Oncology and Metabolism, vol. 2, br. 1, str. 50-59, 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:359339. [Citirano: 17.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:359339
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Current trends in the pharmacotherapy for obesity
AutorSanja Klobučar Majanović
AutorŽeljka Crnčević Orlić
AutorDavor Štimac
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Obesity represents a major global challenge from both healthcare and economic perspectives. Although lifestyle modifications aimed at reducing calorie intake and increasing energy expenditure remain the cornerstone of obesity management, pharmacotherapy can serve as a useful adjunct. Until recently, orlistat was the only medication registered for the treatment of obesity in the European Union (EU). A deeper understanding of the complexity of energy homeostasis has resulted in new pharmacological options for weight reduction. In 2015, two new antiobesity drugs were approved in the EU. These are a fixed combination of naltrexone/bupropion (Mysimba®) and liraglutide at a dose of 3.0 mg (Saxenda®). In addition, lorcaserin (Belviq®) and a fixed combination of phentermine/topiramate (Qsymia®) were introduced into the US market in 2012. However, the European Medicines Agency did not approve their use in the EU. The burden of previous weight loss agents that have been withdrawn due to safety concerns underlines the need for caution and close follow-up of patients undergoing pharmacological interventions for obesity treatment. This article provides an overview of the efficacy and safety of currently available weight loss pharmacotherapies.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEndocrine Oncology and Metabolism
Brojčani podacivol. 2, br. 1, str. 50-59
p-ISSN1849-8922
DOIhttps://doi.org/10.21040/eom/2016.2.6
URN:NBNurn:nbn:hr:184:359339
Datum objave publikacije2016
URL dokumentahttp://bib.irb.hr/812922
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2018-05-30 10:31:22